AACR20: personalized cancer vaccine combination shows promise in solid tumors

Written by Rachel Jenkins, Future Science Group

A personalized cancer vaccine, RO7198457, has shown promise for solid tumors in combination with atezolizumab. The results from the Phase Ib clinical trial have been presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting II (22–24 June 2020). The novel combination demonstrated clinical benefit in patients with advanced solid tumors. The vaccine is a mRNA-based cancer vaccine that is personalized by sequencing a patient’s tumor and blood samples and identifying specific neoantigens. A maximum of 20 neoantigens are selected and the corresponding mRNA is generated, which is then encapsulated in a liposomal formulation for IV administration. A...

To view this content, please register now for access

It's completely free